Founders & Investors
Patrice M. Milos, PhD
Founder MEDLEY GENOMICS
Dr. Milos, a pioneer at the interface of genomics and medicine, currently serves as President and CEO of Medley Genomics - focusing company efforts on genomic analysis tools to decipher the complex genomic heterogeneity involved in many biological conditions. As a co-founder, Patrice has raised seed funding and obtained exclusive world-wide license with Brown University for a powerful suite of software solutions.
Recently, Patrice was President/CEO at Claritas Genomics in Cambridge, MA. Claritas spun out of Boston Children's Hospital to realize the power of combining next-generation DNA sequencing with the clinical expertise of the world’s best pediatric specialists to inform patient care. Highlights included raising Series A/Series B funds, >$15M government contracts from the One Million Veteran Program, transitioning the lab to a world-class, CLIA/ISO-15189 laboratory, launching innovative molecular diagnostic products for pediatric rare disorders and implementing a rigorous approach to portfolio management.
Previously, Patrice served as the Boston Site Head for Pfizer’s Centers of Therapeutic Innovation, establishing key Boston academic medical center partnerships. Dr. Milos also served as the SVP/CSO for Helicos BioSciences, Cambridge, MA and was Executive Director, Molecular Medicine for Pfizer Global Research and Development with responsibilities for genomic technologies and translational biomarkers applied across the Pfizer portfolio.
Dr. Milos serves on the European Commission ULTRAPLACAD External Advisory Board, is an Advisor to Baby’s First Test and SeqLL. Patrice also serves on the BCH Technology Advisory Board, is an active NIH SBIR Grant Review Chair and has served on the National Advisory Council for NIH's Human Genome Research Institute. She sits on several journal editorial boards and has published extensively in genomic sciences. Dr. Milos conducted post-doctoral fellowships at Brown University and Harvard University and earned her MS and PhD degrees at Rensselaer Polytechnic Institute in Troy, NY.
Ben Raphael, PhD
Founder MEDLEY GENOMICS
Ben Raphael is a co-founder of Medley Genomics and a Professor of Computer Science at Princeton University. His research focuses on the design of algorithms for the interpretation of human and cancer genomes, including combinatorial and statistical approaches. Recent areas of emphasis include phylogenetic inference of tumor heterogeneity, network/pathway analysis of genetic variants, and analysis of structural variation in human and cancer genomes. He has led analysis working groups within The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC).
Dr. Raphael received an S.B. in Mathematics from MIT, a Ph.D. in Mathematics from the University of California, San Diego (UCSD), and completed postdoctoral training in Bioinformatics and Computer Science at UCSD. From 2006-2016, he was an Assistant and Associate Professor of Computer Science at Brown University. From 2013-2016, he was also the Director of the Center for Computational Molecular Biology (CCMB) at Brown. He is the recipient of the Alfred P. Sloan Research Fellowship, the NSF CAREER award, and a Career Award at the Scientific Interface from the Burroughs Wellcome Fund.
Barrett Bready, MD
Founder MEDLEY GENOMICS
Barrett Bready, M.D., is Founder and CEO at Nabsys. Dr. Bready is an adjunct professor at Brown University where he teaches Biotechnology Management. He serves as a commissioner of the I-195 Redevelopment District Commission, a large land redevelopment project in downtown Providence with a focus on life sciences and other high technology sectors. He has received numerous awards including, in 2011, Rhode Island Innovator of the Year from Providence Business News. Dr. Bready received an M.D. and an Sc.B. in physics from Brown University, both as part of Brown’s Program in Liberal Medical Education (PLME).
Mr. Horan joined Slater in 2002 and focuses in the area of life sciences and biomedical technology. At Slater, he has led the fund’s investments in: NABsys, a venture-backed company developing DNA sequencing technology; Medrobotics, a developer of integrated systems for robotic surgery; IlluminOss Medical, a medical device company developing minimally-invasive therapy for fracture fixation; Luc Therapeutics (formerly Mnemosyne Pharmaceuticals), a drug discovery venture targeting NMDA receptor function for treating neuro-psychiatric conditions; Tivorsan Pharmaceuticals, a biopharmaceutical company developing a therapeutic for muscular dystrophy; ProThera Biologics, a biopharmaceutical company developing protease inhibitors for treating inflammation; CytoSolv (acquired by Semma Therapeutics), focused on encapsulated cell therapy and regenerative medicine; and MindImmune Therapeutics, a drug discovery venture focused on neuroinflammation. Previous portfolio companies have included: Afferent Corp., which developed neurostimulation systems for stroke rehab and elderly balance; EpiVax, a pioneer in immuno-informatics; Concordia Medical, a developer of biomaterials for regenerative medicine; and Genome Corp., a developer of massively parallel systems for Sanger sequencing.
Mr. Horan began his career in the investment banking business in 1980, when he joined the Capital Markets Group of BankAmerica, San Francisco, CA. In 1986, he joined the venture capital firm of Johnston Associates in Princeton, N.J., one of the original seed-stage investors in the field of life sciences and biotechnology. In 1998, he founded Sachem Ventures LLC, an independent seed-stage venture development firm focused on life science and healthcare markets.
Mr. Horan received his A.B. from Dartmouth College and an M.B.A. from the Tuck School at Dartmouth.
Mr. Katzman is an attorney and business development professional with particular experience in intellectual property commercialization and startup business endeavors. Len Currently serves as Associate Director of Licensing and Business Development at Brown University’s Technology Ventures Office where he focuses on business development and technology commercialization by fostering strategic collaborations with industry through licensing, sponsored research, and launching of new ventures. Prior to joining Brown, Len maintained an active practice as a business attorney concentrating on intellectual property law, technology transactions, business contract negotiations, corporate governance and business counsel. Len’s work is informed by a 15-year career in private industry as a software engineer and computer systems development professional in businesses ranging from startups to Fortune 100 companies. He earned a B.S. in Computer Science from the University of Rhode Island in 1985. In 2000, Len earned his J.D., cum laude, from Rogers Williams University School of Law.